MyMD Pharmaceuticals, Inc.

855 N. Wolfe Street, Suite 623

Baltimore, MD 21205


May 10, 2021




U.S. Securities and Exchange Commission

Division of Corporation Finance

Securities and Exchange Commission

Washington, D.C. 20549


Attention: Ms. Margaret Schwartz
  Mr. Joe McCann


Re: MyMD Pharmaceuticals, Inc., f/k/a Akers Biosciences, Inc.
  Registration Statement on Form S-3
  Originally filed on March 25, 2021, as amended on April 28, 2021
  File No. 333-254698 (the “Registration Statement”)
  Request for Acceleration


Ladies and Gentlemen:


Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, MyMD Pharmaceuticals, Inc. (f/k/a Akers Biosciences, Inc., the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, as amended, so that it may become effective at 4:00 p.m., Eastern Time, on May 11, 2021, or as soon thereafter as practicable.


Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.


  Very truly yours,
  By: /s/ Chris Chapman

Chris Chapman

President, Chief Medical Officer, and Director


cc: Rick A. Werner, Esq., Haynes and Boone, LLP